Presented at the 2024 ASCO Annual Meeting on June 5, the SACI-IO HR+ trial investigated sacituzumab govitecan (SG) with or without pembrolizumab in patients with hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2- MBC).
This phase II study aimed to determine whether adding pembrolizumab (a PD-1 inhibitor) to SG enhances clinical outcomes. Preliminary results showed a non-significant trend toward improved progression-free survival (8.4 vs. 6.2 months, HR 0.76), while overall survival data remain immature. Common side effects included neutropenia, fatigue, alopecia, anemia, and diarrhea.
Though the combination therapy did not achieve statistical significance, further biomarker analyses of TROP2 and PD-L1 expression are ongoing to refine patient selection. Final PFS and updated OS results will be presented in future reports.
A special acknowledgment to all the dedicated researchers who contributed to this important study.
For more details, check out the full study:https://lnkd.in/eG3jwD-p
